News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Health services and systems news

Show

From To
Global health initiatives
Meet the UNAIDS leadership contenders

Opinions vary on who should take the top job from a diverse shortlist that includes former politicians, medical scientists, and an NGO leader.

Published
11 July 2019
From
Devex
PrEP policies and guidelines
Insurance Will Soon Cover HIV Prevention, But Many People Who Need it Still Won't Have Access

When Corey Walsh began using the drug Truvada, the pills were free but the quarterly lab tests and doctors' visits cost almost $400.

Published
11 July 2019
From
Vice
Pharmaceutical industry
GSK touts new Dovato switching data. Is it enough to shake Gilead's HIV lead?

GlaxoSmithKline’s ViiV Healthcare already boasts an approval for Dovato, a two-drug HIV regimen, in newly diagnosed patients. And it just added some new data that aims to at least draw level with market leader Gilead in already-treated patients.

Published
11 July 2019
From
FiercePharma
Harm reduction
UK: Take home naloxone is not reaching those who most need it

Naloxone is key is to addressing the current opioid crisis, but poor systemic distribution means it isn’t saving the lives it should, says Zoe Carre

Published
11 July 2019
From
The BMJ
Long-acting HIV treatment
Lyndra Therapeutics and Gilead Sciences to Collaborate on Development of Ultra-Long-Acting HIV Therapeutics

Lyndra Therapeutics, the company making daily pills a thing of the past, has announced a partnership with Gilead Sciences, Inc. to develop and commercialize ultra-long-acting oral HIV therapies. Gilead will have exclusive rights to Lyndra’s therapeutics platform for ultra-long-acting formulations related to HIV.

Published
10 July 2019
From
Lyndra Therapeutics press release
Epidemiology
Louisiana HIV Rates Are the Lowest in a Decade

Doctors attribute the drop to increased testing and U=U.

Published
10 July 2019
From
POZ
PrEP policies and guidelines
NHS England recommends uncapped PrEP trial access

NHS England have announced five steps towards better access to the HIV prevention drug PrEP, including recommending removing the capped number of places on the ongoing IMPACT Trial. This follows a meeting yesterday between Simon Stevens, chief executive of NHS England, NAT (National AIDS Trust), Terrence Higgins Trust, and PrEPster.

Published
08 July 2019
From
National Health Executive
Clinical trials
EU Calls For Results Of All EU-based Clinical Trials To Be Added To Public Database

The European Commission and European Union medicines regulatory agencies sent an open letter to all sponsors of EU-based clinical trials to remind them of their obligation to publish the results of the trials – both positive and negative – in a public database.

Published
07 July 2019
From
Health Policy Watch
Global health initiatives
Who should lead UNAIDS?

Richard Horton: Who is best qualified to lead an organisation—UNAIDS— that has not only suffered severe reputational loss, but also faces threats to its continuing existence?

Published
07 July 2019
From
The Lancet
Epidemiology
Russia's HIV Epidemic is Growing, Affecting Older Citizens

HIV infections are on the rise and are increasingly affecting Russia’s older population, according to a consumer watchdog report cited by the RBC news website.

Published
07 July 2019
From
Moscow Times
← Prev12345...740Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.